Malignancies of the lymphoid cells, including non-Hodgkin lymphomas (NHLs), Hodgkin lymphoma (HL) and multiple myeloma (MM), occur at much lower rates in Asians than other racial/ethnic groups in the United States (US). It remains unclear whether these deficits are explained by genetic or environmental factors. To better understand environmental contributions, we examined incidence patterns of lymphoid malignancies among populations characterized by ethnicity, birthplace, and residential neighborhood socioeconomic status (SES) and ethnic enclave status.
We obtained data regarding all Asian patients diagnosed with lymphoid malignancies between 1988 and 2004 from the California Cancer Registry and neighborhood characteristics from US Census data.
While incidence rates of most lymphoid malignancies were lower among Asian than white populations, only follicular lymphoma (FL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and nodular sclerosis (NS) HL rates were statistically significantly lower among foreign-born than US-born Asians, with incidence rate ratios ranging from 0.34 to 0.87. Rates of CLL/SLL and NS HL were also lower among Asian women living in ethnic enclaves or lower-SES neighborhoods than those living elsewhere. Conclusions: These observations support strong roles of environmental factors in the causation of FL, CLL/SLL, and NS HL.
Studying specific lymphoid malignancies in US Asians may provide valuable insight towards understanding their environmental causes.
Malignancies of the lymphoid cells, including non-Hodgkin lymphomas (NHLs), Hodgkin lymphoma (HL) and multiple myeloma (MM), are highly heterogeneous with respect to clinical features and patterns of occurrence (
Unfortunately, cancer incidence rates according to measures of migration or acculturation cannot be readily calculated. Although patient birthplace is collected by cancer registries, it is missing in a biased manner for a substantial proportion of patients (
From the California Cancer Registry (CCR), which comprises three of the National Cancer Institute’s SEER program registries(
We included in these analyses 8,638 lymphoid malignancies (6,712 NHL, 526 NHL, and 1,410 MM) occurring in patients from the six Asian ethnic populations that together comprised 92% of all Asian and Pacific Islander patients with lymphoid malignancies in the CCR in the study period. Of these, 2,385 (28%) cases were Chinese, 1,246 (14%) were Japanese, 2,913 (34%) were Filipino, 506 (6%) were Korean, 701 (8%) were South Asian (including Asian Indians, Pakistanis, Sri Lankans and Bangladeshis), and 887 (10%) were Vietnamese. Approximately 5% of patients were originally coded in the registry data as “Asian, not otherwise specified (NOS)”; for 55% of these patients, we were able to determine a more specific Asian ethnic designation based on birthplace and names (first, maiden, last) by applying the North American Association of Central Cancer Registries (NAACCR) Asian/Pacific Islander Identification Algorithm (
Because patients in the cancer registry with unknown birthplace data are more likely to be US-born than those with available data (
Using patient residential address and small area (census tract) information from the US Census, we classified neighborhood SES and ethnic enclave status for all Asian patients diagnosed between 1 January 1998 and 31 December 2002. We considered all Asians together as a single group because detailed ethnicity-specific population estimates are not available for census tracts, and chose the time period in question (i.e., within two years of the 2000 US Census) because census tract estimates are only available for decennial census years. Census tracts were geocoded from patient residential address at time of diagnosis. The 3% of eligible cases whose address could not be precisely geocoded to a census tract were randomly assigned to a census tract within their county of residence. We assigned neighborhood SES using a previously described index (
We defined a neighborhood ethnic enclave as a geographical unit that is relatively more concentrated in terms of its population and language (in this study specific to Asians) than other geographical units in California. To characterize residence in an ethnic enclave, we applied principal components analysis (PCA) (
From the 1990 and 2000 Census Summary File 3 (SF-3), we obtained population counts by sex, race/ethnicity, immigrant status, and five-year age group for the state of California. We also used data from the 20% Integrated Public-Use Microdata Sample of the Census to estimate age- and birthplace-specific population counts for the six Asian groups (
We used SEER*Stat software (
Among the 8,638 Asians diagnosed with a lymphoid malignancy in California in the years 1988 through 2004, the majority (75%) were foreign-born, although this proportion was much lower for Japanese (32%) (
For NHL overall, age-adjusted incidence rates for most Asian ethnic groups were substantially lower than those for non-Hispanic whites (
For most specific lymphoid malignancy subtypes, incidence rates for both US- and foreign-born Asians were lower than those for non-Hispanic whites. The most marked deficits were observed for CLL/SLL (among males, IRR for foreign-born Asians vs. whites=0.22, 95% CI 0.18–0.25; among females, IRR=0.24, 95% CI 0.18–0.30) and NS HL (among males, IRR for foreign-born Asians vs. whites=0.25, 95% CI 0.13–0.37; among females, IRR=0.19, 95% CI 0.13–0.26). However, for TCL and DLBCL (in most ethnic groups), rates were comparable to those for non-Hispanic whites.
For overall NHL, foreign-born Chinese, South Asian, and Vietnamese men and women had consistently lower incidence rates than their US-born counterparts (
For specific subtypes,
For overall HL, rates among foreign-born Asians were approximately half those among US-born Asians. IRR patterns were similar for NS HL, but no nativity differences occurred in rates of MC HL. In data stratified by age, the protective effect of foreign birthplace was limited to young adults of both genders for HL overall; for NS HL, it was apparent for both younger and older females (IRR’s of 0.34 (95% CI 0.23–0.50) for ages 15–44, and 0.32 (95% CI 0.14–0.80) for ages 45 and above).
Although we had limited statistical power for to assess rate changes over time stratified by birthplace, rates did not vary significantly between the periods 1988–1996 and 1997–2004 (data not shown). For overall NHL, rates increased significantly among US-born Chinese and Filipino men and foreign-born Korean men, but not among women of the same groups. IRRs comparing foreign- vs. US-born Asians were generally similar between 1988–1996 and 1997–2004, although for overall HL and NS HL, they were statistically significant only in the latter period (data not shown).
Among Asian men, ethnic enclave status did not impact the incidence rates of overall NHL, DLBCL, FL, CLL/SLL, TCL, MM, overall HL, NS HL, or MC HL (
When we analyzed rates by neighborhood ethnic enclave status and SES jointly, we found that Asian men living in areas with both lower ethnic enclave status and higher SES had significantly higher incidence rates of overall NHL and FL, as well as a marginally higher incidence rate of DLBCL, than Asian men living in areas with both higher enclave status and lower SES (
A role for environmental exposures in cancer etiology can be inferred from changes in cancer incidence after migration from low- to high-risk areas. In a large population-based series of US Asians with lymphoid malignancies, we found that rates were substantially lower in foreign-born than US-born patients for certain lymphoma subtypes, specifically CLL/SLL, FL, and NS HL. Rates of CLL/SLL and NS HL were also significantly lower among Asian women living in ethnic enclaves or lower-SES neighborhoods, compared with rates of Asian women living in lower-enclave or higher-SES neighborhoods, respectively. For HL, the risks associated with higher-SES and lower-enclave neighborhoods were stronger in females than in males. For MM, incidence rates did not differ according to birthplace, ethnic enclave status, or neighborhood SES. We also confirmed that the incidence rates of most subtypes were substantially lower than rates in non-Hispanic white populations; for TCL and DLBCL—the two subtypes for which absolute incidence rates were most similar between Asians and non-Hispanic whites—we did not observe consistent differences in incidence according to birthplace or neighborhood characteristics.
There is little published information regarding the incidence patterns of lymphoid malignancy subtypes among Asians according to detailed ethnicity and birthplace. Our recent analysis based on SEER data documented lower incidence of lymphoid malignancies among six Asian ethnic groups compared with whites(
Differences in cancer incidence rates between Asians who immigrate to the US (and their descendents) and those who remain in Asia have long been considered strong evidence of environmental influences on carcinogenesis, although it is possible that there are also genetic differences among persons who are healthy enough to emigrate. For breast cancer, incidence rates among Chinese and Filipina women born in the US are nearly twice those of women living in Asia, and these differences are increasingly thought to relate to reproductive and dietary changes associated with westernized lifestyle(
The stronger effects of birthplace and neighborhood characteristics for CLL/SLL and HL observed in females than males could, in part, reflect socially determined differences in exposure opportunities (such as those involving children) and biologically determined differences in immune response to exposures(
For HL, the varying impact of birthplace by age group is consistent with prior evidence of differing pathogenesis of HL by age (
Dietary patterns and energy balance/obesity, which also vary by birthplace among US Asians (
By using over 16 years of SEER data from California, we were able to capitalize on the relatively large size of the Asian population in this state and to draw conclusions based on the representativeness of these high-quality, population-based data. We consider the ethnic and birthplace classifications used here to have low probabilities of misclassification or bias. Specific Asian ethnic group was classified directly from registry records or, for those without specific registry information on ethnicity, from applying a validated ethnicity classification algorithm. With this approach, a small proportion (<3%) of patients was excluded from these analyses because of missing ethnic classification. Furthermore, cancer registry classification of specific Asian ethnicity shows good agreement with self-reported information (
Despite these important strengths, our results also may be subject to some limitations. First, we had limited statistical power to analyze certain subgroups, such as specific Asian ethnic groups and uncommon lymphoid malignancies. Second, the heterogeneity in the complex pathologic methods required to diagnose and classify lymphoma cases may have resulted in misclassification of some cases by subtype. Our prior comparisons of cancer registry ICD-O-3 classifications to those obtained from uniform re-review of pathologic specimens suggest a high degree of reliability for the diagnosis of overall NHL and HL(
The markedly lowered rates of lymphoid malignancies among Asians relative to other racial/ethnic groups in the US and among foreign-born Asians relative to US-born Asians have suggested some kind of protection from lymphomagenic processes, but it has been unclear whether this protection relates to genetic or environmental differences. Our data suggest a clear pattern of increased risk of FL, CLL/SLL and HL in Asians according to US birthplace and neighborhood acculturation indicators, and thereby point to a strong influence of environmental factors that change with immigration and acculturation to a westernized lifestyle. Future studies of FL, CLL/SLL and HL designed to collect a wide array of environmental exposure information (and implicated genetic variants of risk) are warranted among Asian immigrant populations in the US and other westernized countries, as they may identify heretofore unrecognized and modifiable causes of these malignancies.
Financial support: This study was supported by the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) program under contract HHSN261201000036C awarded to the Cancer Prevention Institute of California (CPIC).
Other information: The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the SEER Program under contract N01-PC-35136 awarded to CPIC (formerly the Northern California Cancer Center), contract N01-PC-35139 awarded to the University of Southern California, and contract N01-PC-54404 awarded to the Public Health Institute; the Centers for Disease Control and Prevention’s National Program of Cancer Registries, under agreement 1U58DP00807-01 awarded to the Public Health Institute; and R01-ES015552 from the NIEHS and R01-CA121052 from NCI. The ideas and opinions expressed herein are those of the authors and endorsement by the State of California, Department of Public Health the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors is not intended nor should be inferred. The authors thank Sarah Shema and Tim Miller for their contributions to this study.
No authors report any financial conflict of interest.
Demographic and disease characteristics of Asian and non-Hispanic White patients diagnosed with lymphoid malignancies, California, 1988–2004
| Characteristic | Chinese | Japanese | Filipino | Korean | South Asian | Vietnamese | All Asian | Non- Hispanic White | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age at diagnosis (years) | ||||||||||||||||
| 0–29 | 272 | 11% | 58 | 5% | 285 | 10% | 79 | 16% | 131 | 19% | 165 | 19% | 990 | 11% | 7,455 | 7% |
| 30–49 | 381 | 16% | 141 | 11% | 467 | 16% | 97 | 19% | 147 | 21% | 195 | 22% | 1,428 | 17% | 17,158 | 15% |
| 50–69 | 801 | 34% | 433 | 35% | 1,009 | 35% | 173 | 34% | 264 | 38% | 299 | 34% | 2,979 | 34% | 36,730 | 33% |
| 70+ | 931 | 39% | 614 | 49% | 1,152 | 40% | 157 | 31% | 159 | 23% | 228 | 26% | 3,241 | 38% | 49,446 | 45% |
| Sex | ||||||||||||||||
| Male | 1,359 | 57% | 642 | 52% | 1,572 | 54% | 278 | 55% | 419 | 60% | 485 | 55% | 4,755 | 55% | 62,674 | 57% |
| Female | 1,026 | 604 | 48% | 1,341 | 46% | 228 | 45% | 282 | 40% | 402 | 45% | 3,883 | 45% | 48,115 | 43% | |
| Nativity | ||||||||||||||||
| US-born | 620 | 26% | 850 | 68% | 355 | 12% | 72 | 14% | 134 | 19% | 112 | 13% | 2,143 | 25% | --- | --- |
| Foreign-born | 1,765 | 74% | 396 | 32% | 2,558 | 88% | 434 | 86% | 567 | 81% | 775 | 87% | 6,495 | 75% | --- | --- |
| Tumor histology | ||||||||||||||||
| Diffuse large B-cell lymphoma | 621 | 26% | 366 | 29% | 845 | 29% | 131 | 26% | 118 | 17% | 264 | 30% | 2,345 | 27% | 21,920 | 20% |
| Follicular lymphoma | 225 | 9% | 142 | 11% | 147 | 5% | 29 | 6% | 51 | 7% | 67 | 8% | 661 | 8% | 12,027 | 11% |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 183 | 8% | 82 | 7% | 156 | 5% | 23 | 5% | 69 | 10% | 47 | 5% | 560 | 6% | 18,973 | 17% |
| T-cell lymphoma | 207 | 9% | 88 | 7% | 212 | 7% | 58 | 11% | 65 | 9% | 91 | 10% | 721 | 8% | 5,454 | 5% |
| Other non-Hodgkin lymphoma | 682 | 29% | 352 | 28% | 789 | 27% | 159 | 31% | 192 | 27% | 251 | 28% | 2,425 | 28% | 27,091 | 24% |
| Multiple myeloma | 342 | 14% | 170 | 14% | 575 | 20% | 85 | 17% | 123 | 18% | 115 | 13% | 1,410 | 16% | 16,357 | 15% |
| Overall Hodgkin lymphoma | 125 | 5% | 46 | 4% | 189 | 6% | 21 | 4% | 83 | 12% | 52 | 6% | 516 | 6% | 8,967 | 8% |
| Nodular sclerosis Hodgkin lymphoma | 76 | 3% | 27 | 2% | 122 | 4% | 13 | 3% | 51 | 7% | 33 | 4% | 322 | 4% | 5,808 | 5% |
| Mixed cellularity Hodgkin lymphoma | 28 | 1% | 8 | 1% | 31 | 1% | 2 | 0% | 16 | 2% | 11 | 1% | 96 | 1% | 1,532 | 1% |
| Other classical Hodgkin lymphoma | 21 | 1% | 11 | 1% | 36 | 1% | 6 | 1% | 16 | 2% | 8 | 1% | 98 | 1% | 1,627 | 1% |
|
| ||||||||||||||||
| Total | 2,385 | 1,246 | 2,913 | 506 | 701 | 887 | 8,638 | 110,789 | ||||||||
Age-adjusted incidence rates (per 100,000 person-years) of overall non-Hodgkin lymphoma and incidence rate ratios (IRRs) by nativity among Asians and non-Hispanic whites, California, 1988–2004
| Asian ethnic group | Nativity | Males | ||||
|---|---|---|---|---|---|---|
| Cases ( | Incidence rate* | 95% CI | IRR | 95% CI | ||
| Chinese | US-born | 320 | 30.6 | (26.7–34.8) | 1.00 | reference |
| Foreign-born | 775 | 16.9 | (15.2–18.7) | |||
| Japanese | US-born | 396 | 18.1 | (16.3–20.1) | 1.00 | reference |
| Foreign-born | 130 | 30.9 | (25.1–37.6) | |||
| Filipino | US-born | 156 | 23.3 | (18.0–29.6) | 1.00 | reference |
| Foreign-born | 1,026 | 24.1 | (22.3–26.0) | 1.03 | (0.8–1.36) | |
| Korean | US-born | 36 | 16.8 | (7.0–32.4) | 1.00 | reference |
| Foreign-born | 188 | 12.7 | (10.7–15.1) | 0.76 | (0.38–1.84) | |
| South Asian | US-born | 58 | 46.9 | (27.7–73.1) | 1.00 | reference |
| Foreign-born | 244 | 20.1 | (17.1–23.4) | |||
| Vietnamese | US-born | 50 | 66.3 | (36.1–109.5) | 1.00 | reference |
| Foreign-born | 350 | 19.3 | (16.9–22.0) | |||
|
| ||||||
| Non-Hispanic White | 48,816 | 34.5 | (34.2–34.8) | --- | --- | |
| Asian ethnic group | Nativity | Females | ||||
|---|---|---|---|---|---|---|
| Cases ( | Incidence rate* | 95% CI | IRR | 95% CI | ||
| Chinese | US-born | 195 | 15.5 | (13.1–18.1) | 1.00 | reference |
| Foreign-born | 628 | 10.4 | (9.5–11.4) | |||
| Japanese | US-born | 298 | 13 | (11.5–14.7) | 1.00 | reference |
| Foreign-born | 206 | 14 | (12–16.4) | 1.08 | (0.88–1.32) | |
| Filipino | US-born | 106 | 13.5 | (9.8–18.1) | 1.00 | reference |
| Foreign-born | 861 | 15.8 | (14.3–17.3) | 1.17 | (0.86–1.62) | |
| Korean | US-born | 25 | 6.3 | (2.5–13.1) | 1.00 | reference |
| Foreign-born | 151 | 7.2 | (5.9–8.6) | 1.14 | (0.53–2.98) | |
| South Asian | US-born | 37 | 35 | (18.6–58.4) | 1.00 | reference |
| Foreign-born | 156 | 14.3 | (11.8–17.2) | |||
| Vietnamese | US-born | 39 | 34.9 | (17.3–62.7) | 1.00 | reference |
| Foreign-born | 281 | 14.8 | (13–16.9) | |||
|
| ||||||
| Non-Hispanic White | 36,649 | 20.7 | (20.5–20.9) | --- | --- | |
Age-adjusted incidence rates (per 100,000 person-years) of non-Hodgkin lymphoma histologic subtypes, multiple myeloma, Hodgkin lymphoma subtypes, and incidence rate ratios (IRRs) by nativity among Asians and non-Hispanic whites, California, 1988–2004.
| Lymphoid malignancy | Asian ethnic group | Nativity | Males | ||||
|---|---|---|---|---|---|---|---|
| Cases ( | Incidence rate | 95% CI | IRR | 95% CI | |||
| Diffuse large B-cell lymphoma | |||||||
| All | US-born | 314 | 8.5 | (7.5–9.5) | 1.00 | reference | |
| Foreign-born | 961 | 6.5 | (6.1–7.0) | ||||
| Chinese | US-born | 96 | 10.9 | (8.6–13.6) | 1.00 | reference | |
| Foreign-born | 257 | 4.7 | (4.1–5.4) | ||||
| Japanese | US-born | 149 | 6.7 | (5.6–8.0) | 1.00 | reference | |
| Foreign-born | 49 | 11.5 | (8.0–15.7) | ||||
| Other Asian | US-born | 69 | 8.8 | (6.3–11.8) | 1.00 | reference | |
| Foreign-born | 655 | 7.4 | (6.8–8.1) | 0.85 | (0.62–1.20) | ||
| Non-Hispanic White | 12,636 | 8.8 | (8.7–9.0) | --- | --- | ||
|
| |||||||
| Follicular lymphoma | |||||||
| All | US-born | 96 | 2.7 | (2.1–3.3) | 1.00 | reference | |
| Foreign-born | 244 | 1.5 | (1.3–1.7) | ||||
| Non-Hispanic White | 5,981 | 4.1 | (4.0–4.2) | ||||
|
| |||||||
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | |||||||
| All | US-born | 81 | 2.4 | (1.9–2.9) | 1.00 | reference | |
| Foreign-born | 249 | 1.7 | (1.5–1.9) | ||||
| Non-Hispanic White | 11,094 | 7.9 | (7.8–8.1) | ||||
|
| |||||||
| T-cell lymphoma | |||||||
| All | US-born | 122 | 2.2 | (1.8–2.7) | 1.00 | reference | |
| Foreign-born | 305 | 2.0 | (1.8–2.3) | 0.91 | (0.71–1.18) | ||
| Non-Hispanic White | 3,348 | 2.4 | (2.3–2.5) | --- | --- | ||
|
| |||||||
| Multiple myeloma | |||||||
| All | US-born | 128 | 3.8 | (3.2–4.5) | 1.00 | reference | |
| Foreign-born | 614 | 4.3 | (4.0–4.7) | 1.14 | (0.94–1.41) | ||
| Non-Hispanic White | 8,929 | 6.4 | (6.2–6.5) | --- | --- | ||
|
| |||||||
| All Hodgkin lymphoma | |||||||
| All | US-born | 105 | 1.8 | (1.4–2.2) | 1.00 | Reference | |
| Foreign-born | 179 | 1.1 | (0.9–1.2) | ||||
| Non-Hispanic White | 4,929 | 3.4 | (3.3–3.5) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Age <45 years | |||||||
| All | US-born | 82 | 1.7 | (1.3–2.2) | 1.00 | Reference | |
| Foreign-born | 92 | 0.7 | (0.6–1.0) | ||||
| Non-Hispanic White | 3,010 | 3.2 | (3.1–3.3) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Age 45+ years | |||||||
| All | US-born | 23 | 1.8 | (1.1–2.7) | 1.00 | Reference | |
| Foreign-born | 87 | 1.6 | (1.3–2.0) | 0.90 | (0.55–1.51) | ||
| Non-Hispanic White | 1,919 | 3.8 | (3.7–4.0) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Nodular sclerosis | |||||||
| All | US-born | 64 | 1.0 | (0.8–1.4) | 1.00 | reference | |
| Foreign-born | 92 | 0.5 | (0.4–0.7) | ||||
| Non-Hispanic White | 2,900 | 2.0 | (1.9–2.1) | ||||
|
| |||||||
| Hodgkin lymphoma, Mixed cellularity | |||||||
| All | US-born | 15 | 0.3 | (0.2–0.5) | 1.00 | reference | |
| Foreign-born | 47 | 0.3 | (0.2–0.4) | 0.90 | (0.48–1.86) | ||
| Non-Hispanic White | 1,001 | 0.7 | (0.7–0.7) | --- | --- | ||
| Lymphoid malignancy | Asian ethnic group | Nativity | Females | ||||
|---|---|---|---|---|---|---|---|
| Cases ( | Incidence rate | 95% CI | IRR | 95% CI | |||
| Diffuse large B-cell lymphoma | |||||||
| All | US-born | 198 | 4.6 | (4.0–5.4) | 1.00 | reference | |
| Foreign-born | 872 | 4.7 | (4.4–5.0) | 1.01 | (0.86–1.19) | ||
| Chinese | US-born | 49 | 4.5 | (3.3–6.0) | 1.00 | reference | |
| Foreign-born | 219 | 3.6 | (3.1–4.1) | 0.80 | (0.58–1.14) | ||
| Japanese | US-born | 107 | 4.4 | (3.5–5.3) | 1.00 | reference | |
| Foreign-born | 61 | 4.1 | (3.0–5.4) | 0.94 | (0.65–1.34) | ||
| Other Asian | US-born | 42 | 5.1 | (3.3–7.4) | 1.00 | reference | |
| Foreign-born | 592 | 5.5 | (5.0–5.9) | 1.07 | (0.73–1.66) | ||
| Non-Hispanic White | 9,284 | 5.2 | (5.1–5.3) | --- | --- | ||
|
| |||||||
| Follicular lymphoma | |||||||
| All | US-born | 77 | 2.0 | (1.5–2.5) | 1.00 | reference | |
| Foreign-born | 244 | 1.2 | (1.0–1.4) | ||||
| Non-Hispanic White | 6,046 | 3.5 | (3.4–3.6) | ||||
|
| |||||||
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | |||||||
| All | US-born | 44 | 1.2 | (0.8–1.6) | 1.00 | reference | |
| Foreign-born | 186 | 1.0 | (0.9–1.2) | ||||
| Non-Hispanic White | 7,879 | 4.2 | (4.1–4.3) | ||||
|
| |||||||
| T-cell lymphoma | |||||||
| All | US-born | 77 | 1.5 | (1.1–1.9) | 1.00 | reference | |
| Foreign-born | 217 | 1.1 | (1.0–1.3) | 0.75 | (0.56–1.03) | ||
| Non-Hispanic White | 2,106 | 1.3 | (1.2–1.3) | --- | --- | ||
|
| |||||||
| Multiple myeloma | |||||||
| All | US-born | 87 | 2.3 | (1.8–2.9) | 1.00 | reference | |
| Foreign-born | 581 | 3.2 | (2.9–3.5) | ||||
| Non-Hispanic White | 7,428 | 4.0 | (3.9–4.1) | ||||
|
| |||||||
| All Hodgkin lymphoma | |||||||
| All | US-born | 107 | 1.6 | (1.2–1.9) | 1.00 | Reference | |
| Foreign-born | 125 | 0.6 | (0.5–0.7) | ||||
| Non-Hispanic White | 4,038 | 2.8 | (2.7–2.8) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Age <45 years | |||||||
| All | US-born | 91 | 1.7 | (1.3–2.1) | 1.00 | Reference | |
| Foreign-born | 71 | 0.5 | (0.4–0.7) | ||||
| Non-Hispanic White | 2,600 | 2.9 | (2.8–3.1) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Age 45+ years | |||||||
| All | US-born | 16 | 1.3 | (0.7–2.1) | 1.00 | Reference | |
| Foreign-born | 54 | 0.8 | (0.6–1.0) | 0.60 | (0.34–1.14) | ||
| Non-Hispanic White | 1,438 | 2.4 | (2.3–2.5) | --- | --- | ||
|
| |||||||
| Hodgkin lymphoma, Nodular sclerosis | |||||||
| All | US-born | 83 | 1.1 | (0.9–1.4) | 1.00 | reference | |
| Foreign-born | 83 | 0.4 | (0.3–0.5) | ||||
| Non-Hispanic White | 2,908 | 2.1 | (2.0–2.1) | ||||
|
| |||||||
| Hodgkin lymphoma, Mixed cellularity | |||||||
| All | US-born | 11 | --- | --- | 1.00 | reference | |
| Foreign-born | 23 | 0.1 | (0.1–0.2) | 0.64 | (0.28–1.67) | ||
| Non-Hispanic White | 531 | 0.3 | (0.3–0.4) | --- | --- | ||
Standardized to the 2000 U.S. population age standard. Incidence rates with numerator <15 are not computed.
CI: Confidence interval
Age-adjusted incidence rates (per 100,000 person-years) of non-Hodgkin lymphoma and histologic subtypes, multiple myeloma, and Hodgkin lymphoma and histologic subtypes, and incidence rate ratios (IRRs) by neighborhood immigrant enclave status and socioeconomic status (SES) among Asians, California, 1998–2002
| Lymphoid malignancy | Neighborhood characteristic | Males | ||||
|---|---|---|---|---|---|---|
| Cases ( | Incidence rate | 95% CI | IRR | 95% CI | ||
| Overall non-Hodgkin lymphoma | ||||||
| Low enclave status | 343 | 22.6 | (20.2–25.2) | 1.00 | reference | |
| High enclave status | 1,139 | 20.6 | (19.4–21.9) | 0.91 | (0.80–1.04) | |
| Low SES | 715 | 20.2 | (18.7–21.7) | 1.00 | reference | |
| High SES | 767 | 22.1 | (20.4–23.8) | 1.09 | (0.98–1.22) | |
| High enclave status/low SES | 546 | 19.9 | (18.2–21.7) | 1.00 | reference | |
| Low enclave status/low SES | 169 | 20.7 | (17.6–24.2) | 1.04 | (0.87–1.24) | |
| High enclave status/high SES | 593 | 21.4 | (19.5–23.3) | 1.07 | (0.95–1.21) | |
| Low enclave status/high SES | 174 | 24.8 | (21.0–29.0) | |||
|
| ||||||
| Diffuse large B-cell lymphoma | ||||||
| Low enclave status | 112 | 7.6 | (6.2–9.2) | 1.00 | reference | |
| High enclave status | 374 | 7.0 | (6.2–7.7) | 0.92 | (0.74–1.16) | |
| Low SES | 235 | 6.7 | (5.9–7.7) | 1.00 | reference | |
| High SES | 251 | 7.6 | (6.6–8.6) | 1.12 | (0.93–1.36) | |
| High enclave status/low SES | 184 | 6.8 | (5.9–7.9) | 1.00 | reference | |
| Low enclave status/low SES | 51 | 6.4 | (4.7–8.5) | 0.94 | (0.67–1.29) | |
| High enclave status/high SES | 190 | 7.2 | (6.1–8.4) | 1.05 | (0.85–1.31) | |
| Low enclave status/high SES | 61 | 9.0 | (6.8–11.7) | 1.32 | (0.95–1.79) | |
|
| ||||||
| Follicular lymphoma | ||||||
| Low enclave status | 36 | 2.3 | (1.6–3.2) | 1.00 | reference | |
| High enclave status | 106 | 1.8 | (1.5–2.2) | 0.81 | (0.55–1.24) | |
| Low SES | 57 | 1.5 | (1.2–2.0) | 1.00 | reference | |
| High SES | 85 | 2.4 | (1.9–2.9) | |||
| High enclave status/low SES | 48 | 1.7 | (1.2–2.2) | 1.00 | reference | |
| Low enclave status/low SES | 9 | --- | 0.62 | (0.27–1.29) | ||
| High enclave status/high SES | 58 | 2.0 | (1.5–2.6) | 1.19 | (0.79–1.81) | |
| Low enclave status/high SES | 27 | 3.7 | (2.4–5.5) | |||
|
| ||||||
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | ||||||
| Low enclave status | 32 | 2.1 | (1.4–3.1) | 1.00 | reference | |
| High enclave status | 102 | 1.9 | (1.6–2.4) | 0.91 | (0.60–1.42) | |
| Low SES | 64 | 1.8 | (1.4–2.3) | 1.00 | reference | |
| High SES | 70 | 2.2 | (1.7–2.8) | 1.20 | (0.83–1.73) | |
| High enclave status/low SES | 46 | 1.7 | (1.2–2.3) | 1.00 | reference | |
| Low enclave status/low SES | 18 | 2.2 | (1.3–3.5) | 1.30 | (0.70–2.29) | |
| High enclave status/high SES | 56 | 2.2 | (1.6–2.9) | 1.30 | (0.85–1.99) | |
| Low enclave status/high SES | 14 | --- | 1.20 | (0.58–2.27) | ||
|
| ||||||
| T-cell lymphoma | ||||||
| Low enclave status | 37 | 2.2 | (1.5–3.1) | 1.00 | reference | |
| High enclave status | 148 | 2.5 | (2.1–2.9) | 1.13 | (0.77–1.71) | |
| Low SES | 87 | 2.3 | (1.8–2.8) | 1.00 | reference | |
| High SES | 98 | 2.6 | (2.1–3.2) | 1.13 | (0.82–1.54) | |
| High enclave status/low SES | 72 | 2.4 | (1.9–3.1) | 1.00 | reference | |
| Low enclave status/low SES | 15 | 1.7 | (0.9–2.8) | 0.69 | (0.36–1.23) | |
| High enclave status/high SES | 76 | 2.5 | (2.0–3.2) | 1.03 | (0.73–1.47) | |
| Low enclave status/high SES | 22 | 2.8 | (1.7–4.4) | 1.14 | (0.65, 1.92) | |
|
| ||||||
| Multiple myeloma | ||||||
| Low enclave status | 62 | 4.4 | (3.3–5.7) | 1.00 | reference | |
| High enclave status | 202 | 3.8 | (3.3–4.4) | 0.87 | (0.65–1.19) | |
| Low SES | 137 | 4.0 | (3.3–4.7) | 1.00 | reference | |
| High SES | 127 | 3.9 | (3.2–4.6) | 0.97 | (0.75–1.25) | |
| High enclave status/low SES | 101 | 3.8 | (3.1–4.6) | 1.00 | reference | |
| Low enclave status/low SES | 36 | 4.8 | (3.3–6.6) | 1.26 | (0.83–1.86) | |
| High enclave status/high SES | 101 | 3.9 | (3.1–4.7) | 1.02 | (0.76–1.37) | |
| Low enclave status/high SES | 26 | 3.9 | (2.5–5.8) | 1.04 | (0.64–1.63) | |
|
| ||||||
| Overall Hodgkin lymphoma | ||||||
| Low enclave status | 27 | 1.5 | (1.0–2.2) | 1.00 | reference | |
| High enclave status | 84 | 1.2 | (0.9–1.5) | 0.79 | (0.50–1.28) | |
| Low SES | 42 | 1.0 | (0.7–1.4) | 1.00 | reference | |
| High SES | 69 | 1.5 | (1.1–1.9) | 1.46 | (0.98–2.23) | |
|
| ||||||
| Hodgkin lymphoma, Age<45 years | ||||||
| Low enclave status | 12 | --- | --- | 1.00 | reference | |
| High enclave status | 56 | 1.1 | (0.8–1.4) | 1.19 | (0.63–2.45) | |
| Low SES | 21 | 0.7 | (0.4–1.0)) | 1.00 | reference | |
| High SES | 47 | 1.4 | (1.0–1.9) | |||
|
| ||||||
| Hodgkin lymphoma, Age 45+ years | ||||||
| Low enclave status | 15 | 2.6 | (1.4–4.3) | 1.00 | reference | |
| High enclave status | 28 | 1.4 | (0.9–2.0) | 0.53 | (0.27–1.09) | |
| Low SES | 21 | 1.6 | (1.0–2.5) | 1.00 | reference | |
| High SES | 22 | 1.6 | (1.0–2.5) | 0.96 | (0.50–1.89) | |
|
| ||||||
| Hodgkin lymphoma, Nodular sclerosis | ||||||
| Low enclave status | 14 | --- | --- | 1.00 | reference | |
| High enclave status | 49 | 0.7 | (0.5–0.9) | 0.92 | (0.49–1.83) | |
| Low SES | 20 | 0.4 | (0.3–0.7) | 1.00 | reference | |
| High SES | 43 | 0.9 | (0.6–1.2) | |||
|
| ||||||
| Hodgkin lymphoma, Mixed cellularity | ||||||
| Low enclave status | 6 | --- | --- | 1.00 | reference | |
| High enclave status | 16 | 0.2 | (0.1–0.4) | 0.67 | (0.24–2.13) | |
| Low SES | 12 | --- | --- | 1.00 | reference | |
| High SES | 10 | --- | --- | 0.73 | (0.27–1.90) | |
| Lymphoid malignancy | Neighborhood characteristic | Females | ||||
|---|---|---|---|---|---|---|
| Cases ( | Incidence rate | 95% CI | IRR | 95% CI | ||
| Overall non-Hodgkin lymphoma | ||||||
| Low enclave status | 307 | 16.0 | (14.2–17.9) | 1.00 | reference | |
| High enclave status | 921 | 13.7 | (12.8–14.7) | |||
| Low SES | 604 | 13.8 | (12.7–14.9) | 1.00 | reference | |
| High SES | 624 | 14.7 | (13.5–15.9) | 1.06 | (0.95–1.20) | |
| High enclave status/low SES | 442 | 13.2 | (12.0–14.5) | 1.00 | reference | |
| Low enclave status/low SES | 162 | 15.7 | (13.3–18.3) | 1.18 | (0.98–1.43) | |
| High enclave status/high SES | 479 | 14.2 | (12.9–15.6) | 1.08 | (0.94–1.23) | |
| Low enclave status/high SES | 145 | 16.5 | (13.8–19.5) | |||
|
| ||||||
| Diffuse large B-cell lymphoma | ||||||
| Low enclave status | 108 | 5.7 | (4.7–6.9) | 1.00 | reference | |
| High enclave status | 343 | 5.2 | (4.7–5.8) | 0.91 | (0.73–1.15) | |
| Low SES | 235 | 5.3 | (4.7–6.1) | 1.00 | reference | |
| High SES | 216 | 5.3 | (4.6–6.1) | 1.00 | (0.82–1.21) | |
| High enclave status/low SES | 169 | 5.0 | (4.3–5.8) | 1.00 | reference | |
| Low enclave status/low SES | 66 | 6.4 | (4.9–8.2) | 1.28 | (0.94–1.71) | |
| High enclave status/high SES | 174 | 5.5 | (4.7–6.4) | 1.09 | (0.87–1.36) | |
| Low enclave status/high SES | 42 | 4.9 | (3.5–6.7) | 0.98 | (0.67–1.39) | |
|
| ||||||
| Follicular lymphoma | ||||||
| Low enclave status | 32 | 1.6 | (1.1–2.2) | 1.00 | reference | |
| High enclave status | 88 | 1.2 | (1.0–1.5) | 0.80 | (0.53–1.25) | |
| Low SES | 44 | 1.0 | (0.7–1.3) | 1.00 | reference | |
| High SES | 76 | 1.7 | (1.3–2.1) | |||
| High enclave status/low SES | 31 | 0.9 | (0.6–1.3) | 1.00 | reference | |
| Low enclave status/low SES | 13 | --- | 1.26 | (0.60–2.50) | ||
| High enclave status/high SES | 57 | 1.6 | (1.2–2.0) | |||
| Low enclave status/high SES | 19 | 2.1 | (1.2–3.3) | |||
|
| ||||||
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | ||||||
| Low enclave status | 29 | 1.7 | (1.1–2.4) | 1.00 | reference | |
| High enclave status | 60 | 1.0 | (0.7–1.2) | |||
| Low SES | 59 | 1.4 | (1.1–1.8) | 1.00 | reference | |
| High SES | 30 | 0.8 | (0.5–1.1) | |||
| High enclave status/low SES | 39 | 1.2 | (0.9–1.7) | 1.00 | reference | |
| Low enclave status/low SES | 20 | 2.1 | (1.3–3.3) | 1.76 | (0.95–3.11) | |
| High enclave status/high SES | 21 | 0.7 | (0.4–1.0) | |||
| Low enclave status/high SES | 9 | --- | 0.91 | (0.37–1.94) | ||
|
| ||||||
| T-cell lymphoma | ||||||
| Low enclave status | 25 | 1.2 | (0.8–1.8) | 1.00 | reference | |
| High enclave status | 104 | 1.4 | (1.2–1.8) | 1.22 | (0.77–2.00) | |
| Low SES | 52 | 1.1 | (0.8–1.5) | 1.00 | reference | |
| High SES | 77 | 1.7 | (1.3–2.1) | |||
| High enclave status/low SES | 40 | 1.2 | (0.8–1.6) | 1.00 | reference | |
| Low enclave status/low SES | 12 | 1.1 | (0.6–1.9) | 0.95 | (0.44–1.87) | |
| High enclave status/high SES | 64 | 1.7 | (1.3–2.2) | 1.50 | (0.99–2.30) | |
| Low enclave status/high SES | --- | 1.18 | (0.56–2.29) | |||
|
| ||||||
| Multiple myeloma | ||||||
| Low enclave status | 63 | 3.2 | (2.5–4.1) | 1.00 | reference | |
| High enclave status | 211 | 3.3 | (2.9–3.8) | 1.03 | (0.77–1.40) | |
| Low SES | 150 | 3.5 | (2.9–4.1) | 1.00 | reference | |
| High SES | 125 | 3.2 | (2.6–3.8) | 0.92 | (0.72–1.18) | |
| High enclave status/low SES | 112 | 3.4 | (2.8–4.1) | 1.00 | reference | |
| Low enclave status/low SES | 38 | 3.6 | (2.5–5.0) | 1.06 | (0.71–1.56) | |
| High enclave status/high SES | 99 | 3.3 | (2.6–4.0) | 0.95 | (0.72–1.26) | |
| Low enclave status/high SES | 25 | 2.7 | (1.7–4.1) | 0.80 | (0.49–1.26) | |
|
| ||||||
| Overall Hodgkin lymphoma | ||||||
| Low enclave status | 41 | 2.0 | (1.4–2.7) | 1.00 | reference | |
| High enclave status | 68 | 0.9 | (0.7–1.1) | |||
| Low SES | 40 | 0.8 | (0.6–1.1) | 1.00 | reference | |
| High SES | 69 | 1.4 | (1.1–1.8) | |||
|
| ||||||
| Hodgkin lymphoma, Age<45 years | ||||||
| Low enclave status | 28 | 1.9 | (1.2–2.7) | 1.00 | reference | |
| High enclave status | 50 | 0.9 | (0.7–1.2) | |||
| Low SES | 32 | 1.0 | (0.7–1.4) | 1.00 | reference | |
| High SES | 46 | 1.3 | (1.0–1.8)) | 1.37 | (0.84–2.23) | |
|
| ||||||
| Hodgkin lymphoma, Age 45+ years | ||||||
| Low enclave status | 13 | --- | --- | 1.00 | reference | |
| High enclave status | 18 | 0.8 | (0.4–1.2) | |||
| Low SES | 8 | --- | --- | 1.00 | reference | |
| High SES | 23 | 1.6 | (1.0–2.4)) | |||
|
| ||||||
| Hodgkin lymphoma, Nodular sclerosis | ||||||
| Low enclave status | 24 | 1.1 | (0.7–1.7) | 1.00 | reference | |
| High enclave status | 56 | 0.7 | (0.5–0.9) | 0.63 | (0.38–1.08) | |
| Low SES | 31 | 0.6 | (0.4–0.9) | 1.00 | reference | |
| High SES | 49 | 0.9 | (0.7–1.3) | 1.51 | (0.93–2.48) | |
|
| ||||||
| Hodgkin lymphoma, Mixed cellularity | ||||||
| Low enclave status | 9 | --- | --- | 1.00 | reference | |
| High enclave status | 5 | --- | --- | |||
| Low SES | <5 | --- | --- | 1.00 | reference | |
| High SES | 11 | --- | --- | 3.76 | (0.98–21.08) | |
Standardized to the 2000 U.S. population age standard. Incidence rates with numerator <15 are not computed.
CI: Confidence interval